Clinical depression, diagnosed in 5-15% of women during pregnancy, increases the risk of negative pregnancy outcomes including an increased incidence of low birth weight newborns and preterm delivery. Fluoxetine, a selective serotonin reuptake inhibitor, is often prescribed to treat depression due to its efficacy, high margin of safety, and mild side effects. However, fluoxetine initially increases plasma serotonin concentration, and serotonin causes uterine vasoconstriction in sheep, which could result in fetal hypoxemia. To assess fetal fluoxetine effects, late-gestation pregnant sheep were surgically prepared for the measurement of blood gases, heart rate, blood pressure, and uterine artery blood flow (n ϭ 29). Ewes received a 70-mg bolus i.v. infusion of fluoxetine over 2 min in 10 mL of sterile water followed by continuous infusion at a rate of 100 g/min for 8 d (n ϭ 14), or continuous infusion of sterile water (n ϭ 15). Transient decreases in uterine artery blood flow, fetal PO 2 , and oxygen saturation were observed within the first 15 min after fluoxetine exposure, which did not return to normal values by 24 h. Fetal pH decreased and PCO 2 increased over the first 4 h with a return to normal by 24 h. However, there were no differences in uterine artery blood flow, blood gas status, or cardiovascular measures between the control and fluoxetine group over the rest of the 8-d infusion period. Thus, fluoxetine exposure during pregnancy has transient effects on fetal status that may be of developmental consequence if they occur repetitively. Depression occurs in 5-15% of pregnant women, and an additional 10 -15% of women experience postpartum depression (1). A study of general practitioner records in the United Kingdom from 1991 to 1996 showed that FX is the most prescribed SSRI (2). The SSRIs have fewer side effects than tricyclic antidepressants and monoamine oxidase inhibitors and thus are frequently prescribed during pregnancy (3). First trimester in utero exposure to FX does not result in teratogenic effects in humans (4, 5), whereas third trimester exposure has been reported to increase the incidence of preterm delivery, admission to special care nursery, poor neonatal adaptation, and to decrease birth weight (6, 7). However, other studies have found no difference in birth weight, perinatal complications, or neurobehavioral development (8, 9).
Depression occurs in 5-15% of pregnant women, and an additional 10 -15% of women experience postpartum depression (1) . A study of general practitioner records in the United Kingdom from 1991 to 1996 showed that FX is the most prescribed SSRI (2) . The SSRIs have fewer side effects than tricyclic antidepressants and monoamine oxidase inhibitors and thus are frequently prescribed during pregnancy (3) . First trimester in utero exposure to FX does not result in teratogenic effects in humans (4, 5) , whereas third trimester exposure has been reported to increase the incidence of preterm delivery, admission to special care nursery, poor neonatal adaptation, and to decrease birth weight (6, 7) . However, other studies have found no difference in birth weight, perinatal complications, or neurobehavioral development (8, 9) .
Chronic FX treatment enhances serotonin neurotransmission by inhibiting serotonin reuptake by the serotonin transporter. In addition, presynaptic inhibitory 5HT 1A and 5HT 1D/1B receptors are desensitized (9) . Serotonin causes contraction of the human and sheep umbilical artery (10, 11) . Injections of serotonin into the uterine artery in pregnant and nonpregnant sheep results in dose-dependent decreases in UABF ranging from 20% to 50% at doses of 1-10 g (12) . Whether FX interacts directly with serotonin receptors or through changes in plasma levels of serotonin, a decrease in UABF, either chronic or repeated, may be a mechanism for the possible negative effects of third trimester FX exposure. For this reason, we have measured UABF, blood gas status, and fetal growth during maternal FX infusion in late-gestation pregnant sheep.
METHODS
Animals and surgical preparation. Twenty-nine time-bred Dorset/Suffolk cross, pregnant sheep were surgically prepared between 118 and 122 d gestation (term is approximately 145 d). The University of British Columbia Animal Care Committee approved experimental protocols and procedures performed on the sheep and these conformed to the guidelines of the Canadian Council on Animal Care. Surgical procedures have been described in detail previously (13) . Briefly, anesthesia was induced by injection of 1 g pentothal via the jugular vein. After intubation, anesthesia was maintained with 1.5% isoflurane. The uterus was incised and the fetus exposed for the implantation of polyvinyl catheters (Tygon, Akron, OH, U.S.A.) in the trachea, both femoral arteries, a lateral tarsal vein, and the amniotic cavity. Electrodes of Teflon-coated stainless steel wire (Cooner, Chatsworth, CA, U.S.A.) were implanted for measurement of fetal behavioral state. In 11 animals, a Transonic blood flow transducer (Transonic Corp., Ithaca, NY, U.S.A.) was placed around the main uterine artery of the uterine horn containing the operated fetus for the continuous measurement of UABF. All catheters were flushed daily with approximately 2 mL of sterile 0.9% sodium chloride containing 12 U heparin/mL to maintain their patency. Ampicillin (500 mg) was administered into the amniotic cavity daily and intramuscularly to the ewe at surgery and for 3 postoperative days. Sheep were housed in holding pens with other sheep and had free access to food and water after surgery.
Experimental protocol. One preinfusion day preceded an 8-d continuous infusion of sH 2 O (n ϭ 15) or FX (n ϭ 14). On infusion d 1, a bolus injection of 70 mg FX in 10 mL sH 2 O or 10 mL of sH 2 O was given over 2 min into the maternal venous catheter followed by continuous infusion of 2.77 mg/mL FX or sH 2 O at a rate of 0.036 mL/min (i.e. 100 g FX/min) with a Harvard infusion pump (Harvard Apparatus, Millis, MA, U.S.A.). At 0700 h each day, maternal (5 mL) and fetal (3 mL) blood samples were collected for analysis of FX and blood gases. In addition, on the first day of the infusion, blood gas and FX samples were collected at 0 (0700 h), 5, 15, and 30 min and 1, 2, 4, 6, and 12 h after the infusion began.
Blood gas analysis. Blood samples were analyzed for pH, PCO 2 , and PO 2 with an IL 1306 pH/blood gas analyzer (Allied Instrumentation Laboratory, Milan, Italy) and temperature corrected to 39.5°C for fetal samples and 39°C for maternal samples. Hb and oxygen saturation were measured with an OSM-2 Hemoximeter (Radiometer, Copenhagen, Denmark). Glucose and lactate were determined with a glucose/lactate 2306 STAT plus analyzer (YSI Inc., Yellow Springs, OH, U.S.A.).
Physiologic monitoring. Maternal and fetal arterial pressure and heart rate were continuously recorded using a TA-4000 Gould (Gould Instrument Systems, Valley View, OH, U.S.A.) or a Grass K2G (Astro-Med, Montreal, QC, Canada) chart recorder that produced a record at a rate of 2.5 and 3 mm/min, respectively. UABF was measured using a Transonic transittime flow transducer and also recorded on the chart recorder. A PCL-718 data acquisition card (Advantech, Wilmington, MA, U.S.A.) converted the analogue data processed by the chart recorders to digital data that was processed and stored using Labtech software (Labtech, Wilmington, MA, U.S.A.).
Assessment of fetal and postnatal growth. Fetal head (anterior to the ears) and abdominal (anterior to the umbilical cord) circumference were measured at time of surgery and at birth. Lambs were weighed immediately after birth and towel drying, and between 0900 and 1000 h each day postnatally. Ewes and lambs were monitored after birth to ensure the lambs received colostrum and were able to suckle. If required because of multiple gestation or maternal udder problems, lambs were supplemented with commercial lamb milk formula.
Measurement of fluoxetine concentrations. A rapid, sensitive, and selective chiral assay for FX and NFX enantiomers using gas chromatography mass spectrometry with selective ion monitoring developed in our laboratory was used for FX and NFX analysis in plasma (14) . Plasma values are shown for the six animals for whom maternal and fetal blood samples were collected at all time points in the protocol from 0700 h on the preinfusion day to 72 h after FX infusion ceased.
Statistical analysis. Blood gas, cardiovascular, and UABF data were analyzed using repeated measures ANOVA followed by post hoc Fishers t tests to determine the effect of both time and treatment on changes in measurements from preinfusion values during the first 24 h after FX infusion and changes from the preinfusion day on each infusion day using NCSS (Kaysville, UT, U.S.A.). Birth weight and gestational age data were analyzed using unpaired t tests. Results are presented as means Ϯ SEM. Due to the length of the protocol, all parameters were not collected from all animals at all time points. Plasma fluoxetine levels. On infusion d 1 ( Fig. 2) , FX levels in both the ewe and fetus peaked at 5 min after the bolus infusion (173.3 Ϯ 31.4 ng/mL in the ewe and 26.8 Ϯ 3.9 ng/mL in the fetus) and decreased during the first 6 h (46.9 Ϯ 10.4 ng/mL in the ewe and 17.4 Ϯ 1.7 ng/mL in the fetus).
RESULTS
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Plasma concentrations of FX's active metabolite, NFX, increased over the initial 6-h period from 4.5 Ϯ 2.1 ng/mL to 25.3 Ϯ 3.4 ng/mL in the ewe and 0 to 8 Ϯ 1.2 ng/mL in the fetus. Maternal and fetal FX levels progressively increased throughout the 8-d infusion, peaking at 166.5 Ϯ 45 ng/mL on infusion d 7 in the ewe and at 58.9 Ϯ 14.9 ng/mL on infusion d 8 in the fetus. Maternal and fetal plasma NFX levels also increased progressively during the infusion period. Fetal FX plasma levels were 37.1 Ϯ 0.0% of maternal levels from 6 h after the infusion began until the infusion ended.
Acute physiologic changes during fluoxetine infusion. Maternal and fetal blood gas and pH values during the first 24 h of sH 2 23 .5 Ϯ 0.7 to 18.0 Ϯ 1.1 mm Hg. PO 2 returned toward the preinfusion value but remained slightly but significantly decreased for the whole of the first day. There were similar changes in fetal O 2 saturation (Fig. 4) , with an initial decrease from 60.3 Ϯ 5.3 to 41.9 Ϯ 8.5% at 5 min postinjection. The pH decrease was not associated with any change in base excess, which was 0.55 Ϯ 0.68 mEq/L before FX administration and 0.68 Ϯ 0.33 mEq/L at 30 min, the time of the maximum fall in pH. In the CON group, fetal Hb concentration decreased from 10.7 Ϯ 0.4 to 10.0 Ϯ 0.5 g/dL at 5 min and remained at 10.3-10.8 g/dL for the rest of the first day. Hb concentration in the FX fetuses (10.0 Ϯ 0.5 g/dL) was not significantly altered. Figure 5 illustrates the changes in maternal and fetal glucose and lactate concentration during the first 24 h. In both groups, the changes in maternal and fetal glucose concentration were parallel and the levels increased significantly after the feeding 436 of the animals between 1 and 2 h. Maternal and fetal lactate concentrations increased in both groups, along with the rise in glucose. In addition, in the FX-exposed fetuses, there was a greater rise in the first hour of the infusion and the levels remained elevated above the preinfusion value for the remainder of the day. Figure 6 illustrates the changes in maternal and fetal arterial pressure and heart rate during the first 24 h of the experiment. In FX, both fetal (46 Ϯ 3 mm Hg at 0 h) and maternal (92 Ϯ 3 mm Hg at 0 h) arterial pressure were higher than the values in the CON group (fetal, 45 Ϯ 1 mm Hg; maternal, 77 Ϯ 6 mm Hg at 0 h) for the entire 24 h, and for the ewe the differences between the groups were statistically significant at 4 and 6 h. There were, however, no consistent changes in either maternal or fetal heart rate and blood pressure with time. Maternal heart rate (CON, 84 Ϯ 8 bpm; FX, 94 Ϯ 5 bpm at 0 h) was not significantly altered in either group. With FX, fetal heart rate increased significantly from 162 Ϯ 6 bpm preinfusion to 188 Ϯ 
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FETAL RESPONSE TO FLUOXETINE 7 bpm at 1 h and remained elevated at 2 and 4 h. In comparison with CON (167 Ϯ 5 bpm at 0 h), fetal heart rate in FX fetuses was higher at every sampling point on the first day.
Absolute UABF decreased from 489 Ϯ 26 mL/min preinfusion to 378 Ϯ 27 mL/min at 5 min after FX infusion began with a return to 465 Ϯ 26 mL/min by 1 h (Fig. 7A ). This represents a fall to 74 Ϯ 6% of the preinfusion value at 5 min and 77 Ϯ 6% at 15 min with a return to preinfusion values by 1 h (p Ͻ 0.05). No significant changes in UABF were observed in CON.
Daily physiologic changes with fluoxetine infusion. Blood gas status was monitored at 0700 h daily with the preinfusion day and infusion d 1 samples being preinfusion samples. No changes in maternal blood gas status were observed with FX Daily average maternal arterial pressure and heart rate were not affected by maternal FX infusion nor was fetal arterial pressure (data not shown). Compared with the preinfusion day (172 Ϯ 4 bpm), there was a decrease in fetal heart rate on infusion d 2-6 (162 Ϯ 6 and 157 Ϯ 6 bpm, respectively) in FX.
A decrease in fetal heart rate was also observed in CON on infusion d 4 -8 (159 Ϯ 10 and 150 Ϯ 6 bpm, respectively) compared with the preinfusion day (164 Ϯ 4 bpm). Fetal heart rate was significantly higher in FX compared with CON on the preinfusion day of the experiment as well as on infusion d 1, 7, and 8. This is consistent with the data presented in Figure 7 for fetal heart rate measurements at intervals during the first day.
Daily UABF was analyzed for only the first 5 d of the protocol, as the sample was not large enough in FX-treated animals beyond this time point for statistical analysis. No significant difference was observed in the percent change from the preinfusion day value of UABF in CON or FX (Fig. 7B) .
DISCUSSION
This study is the first to examine the possible underlying mechanisms involved in the previously reported negative effects of FX exposure during third trimester in humans. Changes in these variables were measured both acutely and during chronic exposure at clinically relevant plasma concentrations. The results of this study show that maternal i.v. infusion of FX decreases UABF transiently, and this is associated with fetal hypoxemia and respiratory acidemia. This transient response lasts about 12 h with no chronic changes in UABF. Mild alterations of fetal blood gas status were observed throughout the 8 d of FX infusion. No negative birth outcomes were observed in terms of birth weight, gestational age at delivery, or intrauterine growth restriction in FX-exposed fetuses compared with control fetuses.
The maternal FX and NFX concentrations in the present study are similar to those reported in humans. The mean maternal FX concentrations fall within the adult human therapeutic range for FX, which is 35-415 ng/mL in depressed patients taking daily 20 mg doses of the drug (15) . In the fetus, the FX concentration averaged 58.9 Ϯ 14.9 ng/mL at the end of the infusion period. Our study of nine pregnant women on FX therapy found umbilical cord vein concentrations of 7.9 -89.7 ng/mL at delivery (16) . This is similar to the mean value in the fetal lamb on infusion d 8. After a single oral dose of FX in humans, the peak in plasma drug concentration occurs after 5-8 h, and the elimination half-life is 1-4 d (17) . Due to this long half-life, it takes 1-22 mo to achieve steady-state (18) and over this time the mean daily drug concentration would be increasing progressively, likely with daily fluctuations between the peak and trough plasma drug levels. This is somewhat similar to the plasma drug concentration versus time curves resulting from the i.v. administration regimen in the current study, although clearly the initial peak in drug concentration occurs later with oral dosing.
The initial decrease in UABF during the first 30 min of FX infusion is temporally related to the decrease in fetal arterial PO 2 . The results are similar to those obtained by Yaffe et al. (19) , where a 25% reduction in UABF, achieved via partial occlusion of the uterine artery, decreased fetal arterial PO 2 by approximately 5 mm Hg. Thus, it is most likely that the fall in PO 2 (and rise in PCO 2 ) observed during the first day of FX infusion are due to decreased UABF. Although it is possible that the drug also affected umbilical blood flow, this seems . Maternal (squares) and fetal (circles) arterial pressure (A) and heart rate (B) during the first 24 h of maternal i.v. infusion of vehicle (closed symbols, n ϭ 8 and 10 for maternal and fetal arterial pressure, n ϭ 6 and 9 for maternal and fetal heart rate) or FX (open symbols, n ϭ 12 and 12 for maternal and fetal arterial pressure, n ϭ 7 and 8 for maternal and fetal heart rate). (a) Significant difference between control and FX groups; significant difference (p Ͻ 0.05) from preinfusion day in FX group (c).
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FETAL RESPONSE TO FLUOXETINE unlikely. With experimental reductions in umbilical blood flow, there is fetal hypertension and bradycardia (20) , whereas in the FX-exposed fetuses, there was no change in arterial pressure and tachycardia during the period of hypoxemia.
As noted in the "Introduction," serotonin is a uterine vasoconstrictor. Thus, we believe that the FX-elicited fall in uterine blood flow is caused by a rise in plasma serotonin levels, due to drug-induced inhibition of serotonin uptake by platelets. Plasma serotonin concentrations increase immediately after FX injection in humans and rats (21) and we have observed a similar effect on maternal plasma serotonin concentration after a 70 g i.v. bolus dose of FX in two pregnant ewes (Morrison JL, Chien C, Gruber N, Riggs W, de la Presa Owens S, Innis S, Rurak D, unpublished data). In an acute study, a 1-g injection of serotonin directly into the uterine vasculature reduced UABF by approximately 20% (12) .
Fetal PCO 2 increased in the FX-exposed fetuses during the first 12 h of maternal FX infusion. In studies involving experimental reduction of UABF, a tendency toward an increase in PCO 2 has been observed (19) . In addition, significant increases in fetal PCO 2 occur with spontaneous uterine contractures, which reduce uterine blood flow (22) . Inasmuch as we did not observe any changes in base excess in FX, the decrease in pH observed in FX is due to the rise in PCO 2 . Maternal and fetal glucose concentrations rose at 4 h postinfusion in both CON and FX due to feeding between the 1 and 2 h samples. The increases in lactate at these time points are likely due to the increase in glucose (23) , but the significant rise in fetal lactate concentration in the FX group after FX infusion is consistent with the decrease in PO 2 (24) . The main cardiovascular effect observed was the increase in fetal heart rate during the first 6 h of FX infusion. Comparison of Figures 6 and 7 show that the time course for the tachycardia is similar to the time course for the lactic acidemia. Experimental lactic acidemia, similar to that observed with acute reductions in UABF, result in increased fetal PCO 2 and sustained tachycardia (25) .
Chronic FX exposure caused only minor alterations of fetal blood gas status. It should be noted that fetal PO 2 (although not significant in CON) and oxygen saturation decreased throughout the 8-d infusion period in both CON and FX, although the magnitude of the fall was greater in FX. Over this time period, UABF in FX and CON were not different, and in neither group did it fall. Thus, the reduced fetal oxygenation over this time period was not due to reduced UABF. The lack of change in the FX animals is consistent with the reported effects of chronic FX treatment on serotonin levels in other species. Although acute FX treatment increases plasma serotonin concentration, chronic FX treatment causes a decrease in plasma and platelet serotonin levels in humans and mice (26, 27) . Weight-normalized umbilical blood flow decreases progressively in late gestation in the sheep (28) , and this may be associated with a progressive fall in vascular PO 2 (29) . This would explain the fall in fetal oxygenation during the infusion period observed in both CON and FX. The decrease in fetal heart rate in both CON and FX over the 8 d of infusion is consistent with previous findings of a fall in heart rate with increasing gestational age (30, 31) .
Thus, the major effects of FX on the fetus in the current study occurred on the first day consisting of transient hypoxemia, respiratory acidemia, hyperlactic acidemia, and tachycardia of approximately 6 h duration. Changes of this duration and magnitude would not be expected to affect either gestational length or fetal growth. This is consistent with the lack of differences in gestational length and birth weight in the CON (6) and Goldstein (7) that found an increase in preterm delivery and lower birth weight in fetuses exposed to FX during the third trimester. It is possible that the severity of the underlying depression requiring pharmacological treatment into the third trimester may have resulted in the adverse outcomes in these studies. Differences in lifestyle such as increased smoking and alcohol consumption rather than a direct pharmacological effect of FX may also have also been responsible (7). Alternatively, it is possible that exposure to FX throughout most or all of pregnancy may be required to result in preterm delivery or reduced birth weight.
Although there was no apparent differences in intrauterine growth between the two groups, postnatal growth in the FXexposed lambs was significantly lower than in the CON animals on d 2 with a rebound on d 5. The transient slowing of growth in the FX group may reflect the poor neonatal adaptation that has been reported in human infants exposed to FX in the third trimester by Chambers et al. (6) , and more recently by Cohen et al. (32) . This comprises several features including jitteriness, respiratory difficulties, hypoglycemia, lethargy, and poor tone, some of which could impair sucking behavior. Such behavior could result from altered brain development due to in utero exposure to FX, or from pharmacologic effects of the a Significant difference between control and FX groups; c significant difference from preinfusion day for the FX group. Preinf, preinfusion day; Inf, infusion day.
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FETAL RESPONSE TO FLUOXETINE drug still present in the infants in the early postnatal period. In both the fetal lamb and human, there is no evidence for an ability to metabolize FX, and in human infants at the time of phenylketonuria testing (i.e. at 2 d following birth), the plasma FX concentration is the same as in cord blood at delivery (16) . A similar situation in the FX exposed lambs could have impaired feeding behavior and resulted in the transient slowing of growth. Although we did not notice any abnormal behavioral features in these animals, a systematic examination was not conducted. In the human studies (6, 32) , postnatal weight gain was not reported. It may be clinically relevant for future human studies to include postnatal growth estimates.
The FX-elicited transient changes in fetal PO 2 and PCO 2 are similar in magnitude to those occurring with contractures and fetal skeletal muscle activity, which are normal features of fetal life (22) . However, these physiologic events last only several minutes, whereas the FX-induced decrease in UABF was significant for 30 min whereas PO 2 decreased for 24 h. In addition, pulsatile administration of oxytocin to pregnant ewes from 96 d gestation until term to increase the frequency of contractures and hence the episodes of fetal hypoxemia is associated with accelerated cardiovascular and neurologic maturation (33, 34) . As noted earlier, daily oral FX dosing in humans likely results in daily fluctuations in plasma FX levels, i.e. a peak in concentration followed by a trough. If this leads to daily FX-induced decreases in UABF and fetal vascular PO 2 of the magnitude and duration that occurred on the first day of drug infusion in the current study, there could be impacts on fetal growth and development.
In summary, the primary effects of maternal 8-d i.v FX infusion were a transient reduction in UABF and fetal oxygenation over approximately 1 and approximately 24 h, respectively, on the first infusion day, with no significant antenatal changes thereafter. However, postnatal weight gain was transiently decreased in the FX-exposed lambs. Further studies are warranted to extend our observations, particularly to determine whether the maternal plasma FX concentration profile associated with a daily oral dosing regimen results in a daily decrease in UABF and fetal hypoxemia. In addition, more information on postnatal behavior and weight gain in infants exposed to FX in utero would be very useful. Such data are necessary to fully assess the safety of FX and similar drugs in pregnancy.
